Medical laboratories play a key role in patient care necessitating that they design and implement a QC program to ensure quality and reliability of results. Fundamental elements of any laboratory's quality management system include detailed standard operating procedures (SOPs), appropriate documentation, analyzing and monitoring QC, and external quality assessment/ proficiency testing.
to ensure correct specimen procurement (preanalytical), they must implement appropriately documented internal quality control (IQC) procedures designed to continually monitor their analytical test systems to ensure accurate and precise results are reported (analytical) and must correctly report results in a timely fashion (post-analytical). 2, 3 Careful monitoring of the analytical test system using appropriate QC and corresponding QC rules effectively identifies potential errors and establishes reliability of patient results. 2 A CBC, including leukocyte differential, is one of the most common tests performed in the clinical laboratory. Along with clinical history, the CBC may be the first indication of a primary hematological abnormality, aiding the clinician with diagnosis and patient management. 4 Further information may be provided by new quantitative parameters available on advanced hematology analyzers. 5 With pressures for laboratories to increase productivity while decreasing costs, many are implementing auto-verification of CBC results, increasing the importance of reliable IQC. 6 Limited references and literature exist to guide laboratories to a standardized method of performing and monitoring IQC.
IQMH is a not-for-profit corporation without share capital, in- 
| MATERIAL S AND ME THODS
An online survey was developed and distributed to all 184 Ontario laboratories licensed to perform CBC and automated leukocyte differential count in November 2012. Results were collected electronically and assessed using MSExcel ® .
Results were evaluated and shared with participants in 2013.
Based on these data, the IQMH Hematology Scientific Committee revised previously published Consensus Practice Recommendations (2005) to update changes in current practice.
The process for the creation of the IQMH Hematology Consensus
Practice Recommendation (CPR)-QC in Hematology document followed the following steps:
(i) The Hematology Scientific Committee identified that participating hematology laboratories had variable QC practices based on responses to their PT survey challenges.
(ii) A patterns-of-practice survey was developed and distributed to all PT participants in November of 2012.
(iii) The results of the Hematology QC patterns-of-practice were evaluated, and feedback was provided to the participants in the form of committee comments.
(iv) Based on the review of the current practices in participating
Hematology laboratories and a current literature review, the Hematology Scientific Committee developed an updated IQMH CPR for QC in Hematology.
(v) The revised IQMH CPR was circulated to stakeholders for feedback and acceptance.
(vi) The stakeholder feedback was reviewed by the Hematology Scientific Committee, and final edits were made to the document which was then shared with participants in IQMH's
Internet-based application for client access.
One of the outcomes of this patterns-of-practice survey was considerable variation in precision goals reported by laboratories. As a result, the IQMH Hematology Scientific Committee developed precision goals in 2015 to provide guidance for laboratories in setting appropriate precision limits for routine hematology parameters by searching current published literature and comparing the data with the IQMH APLs as well as considering medical decision points, clinical needs, and the achievable precision with the use of current state-of-the-art technology.
| RE SULTS
All 184 laboratories responded and identified as being affiliated with: 
| Types of QC materials
All responding laboratories indicated they routinely use three levels of commercial QC material (low, normal, high). Ninety-seven percent of laboratories purchase QC material from the analyzer manufacturer, 2% from a third-party source and 1% purchase from the same manufacturer and a third-party source. Eighty percent of laboratories reported using an additional in-house patient QC.
| Frequency of Running QC
Fifty-nine percent of laboratories run commercial QC at the beginning of each day, 20% at the beginning of each shift, 35% when the analyzer has not been used for a predefined time and 3% at the beginning of each defined analytical run. Thirty-five per cent of laboratories reported "Other" and responses included: running commercial QC following maintenance, calibration, reagent change, during troubleshooting, when in-house patient control result is outside of the acceptable range and when there is a patient sample to run for body fluid or reticulocyte count.
Of the 147 laboratories indicating they run in-house patient quality control samples, 66% run the QC when the analyzer has not been used for a defined time, 32% at the beginning of each defined analytical run, 14% at the beginning of each shift, 10% at the beginning of each day, and 3% at the beginning and end of each defined analytical run. Of the 75 laboratories that selected "Other,"
responses included running the patient control every four hours or less, every 10-50 patient samples, when the reagent is changed, every 6-12 hours, when switching between modes and when the compressor is off.
A comparison of the commercial versus in-house patient control frequency is shown in Figure 1A .
| Monitoring internal quality control
Ninety-eight percent of the laboratories stated that they have established QC limits. Laboratories were asked to identify criteria used to establish QC limits with results summarized in Figure 1B . One hundred and seven of 181 (59%) laboratories reported that a combination of more than one source was used. Responses from the 23% selecting "Other" included limits from their organization's professional group, medical director, regional group, or their laboratory's past practice.
Participants were asked to indicate which "QC rules" were applied to their QC data with results and definitions of Westgard Rules 7 summarized in Table 1 .
Twenty-three percent of participants reported "Other, specify" Participants were asked to specify how they monitor quality control data. Multiple responses were received which indicated that 50% 
| Comparison of multiple analyzers in the same site
Participants were asked if they performed multiple analyzer comparison using patient samples; 183 laboratories responded. Five responses were excluded since there were inconsistencies in their responses. Of the 178 laboratories, 100 (56%) had multiple instruments on site. Of the 100 laboratories with multiple instruments, 99% perform multiple instrument comparisons; 37% daily, 22%
weekly, 13% monthly, 19% biannually, and 9% selected "Other,"
and provided different frequencies. Of these 100 laboratories, 95% used patient samples and 4% QC materials for comparisons.
These laboratories indicated they used the following methods to determine acceptability between multiple instruments: published precision goals (41%), IQMH APLs (80%), published clinical decision limits (10%), biological variation-based analytical CV (27%).
Participants were able to select more than one method, and the data collected demonstrated that they used more than one method. 
| Follow-up of a QC failure

| Documentation of failed QC investigation
Participants were asked to select the details included in an investigation of a failed QC rule in their troubleshooting procedure; results are summarized in Table 2 .
| Risk assessment
Laboratories were asked if they perform a risk assessment to improve patient safety and to indicate mechanisms used to identify potential risks. Although only 128 (71%) laboratories stated they use risk assessment tools, 142 submitted responses indicating the mechanisms used for risk assessment (Table 3) . Responses provided for "Other" included use of root-cause investigation, discussions at regional hematology meetings, audit results, educational presentations, and manufacturer bulletins to identify potential risks.
| Precision goals
Laboratories were asked to provide precision goals, and the results demonstrated considerable variation. For the leukocyte count, responses for CV ranged from 0.5% to 15%, erythrocyte count 0.2%
to 15%, and platelets 1.9% to 25%. All responding laboratories indicated they routinely use three levels of commercial QC material (low, normal, high). The use of three levels of control material allows application of additional QC rules, improving detection and interpretation of measurement error. 8 Types of materials used were also very similar. All laboratories reported using commercial QC material from either the same manufacturers or a third-party supplier. In addition, 80% of the laboratories also used in-house patient QC materials. Several factors should be considered when choosing what QC to run including matrix, cost, stability, ease of use, and the laboratory's intended application. If from a different source, it must be hematology analyzer specific. This is due to unique interactions between the simulated control material and the specific method/reagent system used. 8 In-house patient QC has the advantage of being the same matrix as patient samples and can also be a method for verification of laboratory precision. 9 Considerable differences were observed in the selection and frequency of QC runs, limits, and rules used to monitor IQC.
When determining frequency of QC measurements, laboratories should consider if the assay system operates in batch or continuous measurement mode. 8 Batch measurement is a situation where all patient samples and QC materials are run in a defined time with definitive start and end times, while in continuous measurement mode patient samples are run indefinitely unless the continuous mode is interrupted for maintenance or loading the assay system components. 8 In batch mode analysis, running QC samples at the beginning and end of the batch is good QC practice and depending on the assay stability additional QC samples may be run in between. There was considerable variation between laboratories in selecting QC rules. Most (85%) of the laboratories that participated in the survey used three or more QC rules while monitoring QC.
While multirule QC procedures may be more complex, they provide better performance than the single 1 2s and 1 3s rules. The 1 2s
rule is very sensitive in detecting errors; however, its probability of false rejections is 5%, that is when used alone, 1 of 20 results are incorrectly rejected; therefore, 1 2S is recommended as a warning rule.
On the other hand, 1 3s rule has very low probability of false rejection rate; however, its probability of error detection is low. Use of multirule QC procedures decreases probability of false rejections, while increasing probability of error detection. 7 For high precision modern measurement procedures that are operating in a 5-6 sigma level in respect to medically required analytical performance, less strict control rules such as 1 3s or 1 4s may be sufficient. 8 Table 4 .
Laboratories should calculate their own standard deviation for each control lot for their QC limits. Precision goals from manufacturers and other sources should only be used as guidance, as reliable statistics are determined by testing a number of samples over an appropriate number of days to provide a representative data sample.
7,8
The Clinical and Laboratory Standards Institute (CLSI) doc- compare results, and it is good practice to use normal, abnormal low and abnormal high samples for WBC, hemoglobin, and platelets. Patient controls may be used but stability and acceptable limits should be predetermined, that is, established at the time of instrument installation.
Frequency of control material
Commercial QC material should be run at least once per day and after any calibrations. Patient control may be run with reagent changes, following lot changes, maintenance, and throughout the analytical run. Controls should be run at the beginning and end of an analytical run.
Monitoring of quality control
Select multiple QC rules that detect clinically important errors while minimizing false rejections; (1). Eliminate control rules that have a high probability of false rejections (2) . Select a combination of rules that have at least one rule for random error and one rule for systematic error (3). Assess the probabilities for false rejection and error detection using the combination of rules (4) . Choose the total number of control measurements to provide the desired probability of error detection Use a tracking system to monitor QC such as a standardized control chart; a Levey-Jennings chart or QC software that is readily available for review by all laboratory staff.
Determination of target limits
To validate the reliability of calculated statistics 20 QC points are recommended to establish the target mean; at least ten runs are recommended for CBCs.
Run the new lot number concurrently with the old lot numbers.
A patient sample may be used to rule out matrix effect and results should fall within the laboratory's precision goals. A good practice is to use both a normal and abnormal sample.
For laboratories with multiple analyzers, it is recommended to set individual target means and SDs for commercial QC on each analyzer.
Out-of-control situations and investigation
The development of a good QC plan should be based on the events of the process, identification of the preventative action, and the control measures for their detection. In order to troubleshoot assay problems, there must be a system in place to document actions that have taken place in the testing system.
When a QC failure is detected, testing must be discontinued on the analyzer for the assay until the root cause can be determined and effective corrective actions implemented according to a documented protocol.
Repeat testing of patient samples from the last acceptable quality control is recommended.
Risk management
Map the QC process, identify where failures may occur and brainstorm potential failures and causes, then determine the frequency and type of controls needed to ensure the accuracy of results and therefore minimize risk to patients.
TA B L E 5 IQMH consensus practice recommendations for quality control practice the laboratories stated that they would repeat the patient samples starting from the last acceptable quality control.
The majority of participants use risk management methods to mitigate patient risks. The concept of risk management is based on identifying hazards and estimating the probability and severity of harm, 11 an important part of patient safety. IQMH Consensus Practice Recommendations for Quality Control Practice are summarized in Table 5 .
| CON CLUS ION
Laboratories face many challenges, including increasing workload with limited resources. Current automated platforms must be closely monitored with good IQC programs providing high probability of detecting systemic and random errors and minimizing false rejection of test results to optimize productivity. Establishing an IQC system to ensure patient safety by monitoring, detecting, and eliminating errors potentially causing harm to a patient is an integral part of a quality management system.
The recommendations presented here are intended to be used as guidance for implementing QC systems based on the consensus of current practice in routine hematology in Ontario and evidence from published literature. They aim to assist laboratories in creating a QC plan and include recommendations that can be used in mitigating risk by reducing occurrence to ensure reporting of reliable patient results.
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